SCHEMBL9892920

SCHEMBL9892920

CC(C)(C)OC(=O)N1CC[C@H]1C(=O)Nc1nnc(C(C)(C)C)s1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.53
TSHR P16473 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.49
NPC1 O15118 3/20 0.47
NPSR1 Q6W5P4 2/20 0.45
LMNA P02545 1/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
CYP1A2 P05177 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
GLS O94925 2/20 0.43
USP30 Q70CQ3 1/20 0.43
SCN4A P35499 1/20 0.42
RAB9A P51151 2/20 0.42
MAPT P10636 3/20 0.41
DGAT1 O75907 1/20 0.41
SCN5A Q14524 1/20 0.41
SCN3A Q9NY46 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9108193 0.93 CNR2 (0.59) CNR2TSHRL3MBTL1NPC1NPSR1
SCHEMBL9108198 0.93 CNR2 (0.59) CNR2TSHRL3MBTL1NPC1NPSR1
SCHEMBL3786160 0.92 CNR2 (0.55) CNR2TSHRL3MBTL1NPC1NPSR1
SCHEMBL3786164 0.92 CNR2 (0.55) CNR2TSHRL3MBTL1NPC1NPSR1
SCHEMBL9892269 0.83 CYP1A2 (0.54) CNR2TSHRL3MBTL1NPC1NPSR1
SCHEMBL9107799 0.81 CNR2 (0.44) CNR2TSHRL3MBTL1NPC1NPSR1
SCHEMBL9892892 0.78 CNR2 (0.53) CNR2L3MBTL1NPC1NPSR1LMNA
SCHEMBL9892876 0.77 ATAD2 (0.59) CNR2TSHRL3MBTL1NPC1NPSR1
SCHEMBL9892884 0.74 L3MBTL1 (0.68) TSHRL3MBTL1NPC1NPSR1LMNA
SCHEMBL16238715 0.74 L3MBTL1 (0.55) CNR2L3MBTL1NPC1NPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443107-B1 AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2018-08-08 EP disclosed
US-8383615-B2 Azetidine 2-carboxamide derivatives which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-02-26 US disclosed
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-07 US disclosed
WO-2010147791-A1 AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 CNR2 1/4885TSHR 1019/4885L3MBTL1 4866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.